ATMP Sweden’s Post

Some exciting job opportunities being advertised right now! CCRM Nordic  is looking for a Chief Financial Officer (CFO) and Process Development Manager & Team Lead. Find them all on our website SmartCella Holding AB is looking for a Senior Scientist Analytical Development, Flow Cytometry and a Process Development Scientist/Sr. Scientist. Karolinska Institutet Biträdande lektor i mot cancer. Karolinska University Hospital Föreståndare till Karolinska ATMP-centrum. Cellcolabs Medical Advisor and finally Asgard Therapeutics Scientist/Senior Scientist in vitro immuno-oncology, -based therapeutics.

The 8th NextGenNK newsletter is out! Read about the centre's 5 year evaluation, Vycellix Sweden, NK cell scientist Andreas Lundqvist and about leading developments in engineering immune-evasive allogeneic cells for cellular immunotherapies. https://lnkd.in/gdF9yM7j

Welcome Elicera Therapeutics AB to ATMP Sweden membership! A stellar example of the spin out of Swedish innovation 😍 If you missed our article on how their i-TANK technology tricks the immune system into thinking the tumour is a bacterial infection.....you can read up here https://lnkd.in/gM7KeW9X. ABOUT Elicera Therapeutics AB is a cell and gene therapy company in the clinical phase developing the next generation iTANK-enabled CAR T-cell therapies and oncolytic viruses. The company has two ongoing Phase I/II clinical studies: The CARMA-study (CAR T-cell therapy for treatment of B-cell lymphoma) and the AdVince-study (oncolytic virus (OV) for the treatment of neuroendocrine tumours. In addition Elicera is developing two candidates in the preclinical phase: ELC-401 (CAR T-cell therapy for treatment of glioblastoma) and ELC-201 (OV for treatment of solid tumours). The proprietary iTANK-platform aims to meet two of the biggest challenges of CAR T-cell therapies for the treatment of solid tumours: a very heterogenous ett mycket heterogent target antigen expression and a hostile tumour microenvironment. iTANK has been demonstrated to enhance the function of CAR T-cells by activating a parallel immune defense against the tumour via CD8+ killer T-cells. This strategy is expected to have broad application to induce attack on the majority of tumour targets on cancer cells. The iTANK-platform can be universally adapted to other CAR T-cell therapies.

We are proud to welcome Key2Compliance to ATMP Sweden membership! Key2Compliance has been heavily involved in ATMP education already with CAMP. Available on demand are their GMP Basics ATMP Edition, GMP Basics for ATMP and the virtual reality platform for advanced training introduction to working in a cleanroom. If there are any aspects of ATMP training you are interested in developing, feel free to reach out and we can put you in touch! See the full membership list here https://lnkd.in/gQRndwX5 ABOUT At Key2Compliance, we make complex things easier for organizations within Pharma, Medical Device and IVD. With over 70 dedicated professionals, we offer expert consulting and specialized training. As your trusted partner, we always prioritize your success, ensuring a smooth journey guided by expertise and customer-centric values. For our ATMP customers, we can offer: * QA consultancy services – to understand, develop and maintain compliance. 
E.g.: QA support, GMP compliance for ATMP and other GXP compliance, quality management systems (QMS), audits, validation/qualification, gap analysis and quality risk management.   * Training and courses – public, customized, and on-demand trainings 
Basic and advanced trainings within e.g.: regulatory affairs, GMP for ATMP, GXP, Validation Our senior experts in GXP have hands-on ATMP experience, and we have successfully trained and supported ATMP customers, both companies and hospitals, in Sweden and internationally. Find out more on their website https://key2compliance.com Sara Falkenklint